Cytochroma

Diverse, functional, and scalable human cell models that reflect real-world genetic variability.

What Cytochroma Does

Cytochroma manufactures high quality iPSC-derived cells for preclinical testing and disease modelling.

We offer every cell type from every donor, allowing comprehensive, donor-matched model systems across diverse populations.

Build 3D multicellular “mini-organs” and replicate a range of metabolic disorders from MAFLD, MASH to fibrosis. Or contact us let our experts build, screen and deliver the data you need.

Key Highlights

01

Diverse, Predictive Models:

Cytochroma provides iPSC-derived models from genetically diverse male and female donors aligning with FDA recommendations to improve inclusivity in drug development.

01

Diverse, Predictive Models:

Cytochroma provides iPSC-derived models from genetically diverse male and female donors aligning with FDA recommendations to improve inclusivity in drug development.

02

Functional Liver and Heart Models:

Cytochroma's mature hepatocytes and self-organising cardiac microtissues are ideal for high-throughput screening, enabling early detection of toxicity and disease progression.

02

Functional Liver and Heart Models:

Cytochroma's mature hepatocytes and self-organising cardiac microtissues are ideal for high-throughput screening, enabling early detection of toxicity and disease progression.

03

Custom Differentiation Services:

Didn’t find what you need? Cytochroma offers bespoke iPSC differentiation and organoid development services—tailored to your targets, timelines, and therapeutic goals. No challenge is too big.

03

Custom Differentiation Services:

Didn’t find what you need? Cytochroma offers bespoke iPSC differentiation and organoid development services—tailored to your targets, timelines, and therapeutic goals. No challenge is too big.

Diverse donors, consistent results

Why we need increased diversity in preclinical testing

Cytochroma offers one of the most genetically diverse panels of iPSC-derived human cell models available—providing matched cell types from both male and female donors across a range of ethnic backgrounds. This level of diversity is unmatched in the market.
Regulatory agencies like the FDA increasingly require evidence that new drugs are safe and effective across different patient populations. By using multiple, diverse donors from the earliest stages of preclinical testing, Cytochroma enables more predictive, translatable data—reducing risk of failure in later clinical trials and supporting regulatory approval.

Our donor-matched, multi-lineage panels allow pharma teams to assess variability in drug response and toxicity upfront—accelerating the development of safer, more inclusive medicines.

Regulatory requirements

Regulatory bodies are increasingly emphasising the importance of including both genders and diverse genetic backgrounds in preclinical studies. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued guidelines encouraging more representative preclinical research. Complying with these guidelines not only expedites the drug approval process but also ensures that the drug's safety and efficacy are thoroughly evaluated across varied populations.

With the FDA Modernization Act 3.0 supporting non-animal testing, pharma and biotech are rethinking preclinical development. While others are just adapting, Cytochroma's flexible, human-relevant approach aligns its assays and models to the specific biology, disease context, and regulatory goals—empowering teams to generate meaningful data earlier and de-risk decision making.

Incorporate diversity into your drug development journey

Contact us today to find out more about our diverse stem cell library and how it can help de-risk your drug development, predict adverse reactions early on and ensure clinical success.